BRAF and melanoma: Moreover, our study of real-world clinical practice was the largest and included 2.5-fold more patients with BRAF-mutant advanced melanoma compared to those of the above-mentioned study (382 vs. 152 patients) and demonstrated increased median OS (22.6 months) and 2-year OS (47.2%) compared to the earlier reported study [30] in patients receiving the first-line targeted therapy.